Ipamorelin and CJC-1295: What the Research Shows About This Popular GH Combination

The ipamorelin CJC-1295 combination is the most searched growth hormone peptide protocol in the United States, with search volume climbing from roughly 27,000 monthly queries in late 2025 to over 60,000 by mid-2026. For a category of compounds that have never been FDA-approved for any human indication, that trajectory reflects something real: a large and growing number of people are interested in what these peptides do, whether the research supports the interest, and whether they are actually available through legitimate channels right now.

Those last two questions have different answers. The research on the individual compounds and their combined mechanism is genuinely interesting, and we will cover it thoroughly. The regulatory picture is more complicated, and it has shifted significantly over the past 18 months in ways that are still actively evolving. Both deserve an honest treatment, which is what this article provides.

What Ipamorelin and CJC-1295 Are

The ipamorelin CJC-1295 stack combines two distinct classes of growth hormone secretagogues, compounds that stimulate the body’s own pituitary gland to produce and release growth hormone rather than introducing synthetic GH directly. The two compounds work through different receptors, which is the scientific basis for combining them.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the naturally occurring hypothalamic signal that tells the pituitary to release GH. It consists of the first 29 amino acids of native GHRH with four amino acid substitutions at positions 2, 8, 15, and 27, modifications designed to increase resistance to enzymatic degradation and improve receptor binding. The version with a Drug Affinity Complex (DAC) moiety attached at the C-terminus binds to albumin in the bloodstream, extending its half-life to approximately 6 to 8 days compared to the minutes-level half-life of native GHRH. The version without DAC (also called Modified GRF 1-29) has a shorter half-life of approximately 30 minutes and produces a more pulsatile GH response.

Ipamorelin is a synthetic pentapeptide (five amino acids) that belongs to the family of growth hormone-releasing peptides (GHRPs). Where CJC-1295 activates the GHRH receptor, ipamorelin activates the ghrelin receptor (also called the GH secretagogue receptor, GHSR-1a) on pituitary somatotrophs. It was originally designated NNC 26-0161 and was developed from studies on the metenkephalin structure. Ipamorelin is notable for its high selectivity: it stimulates GH release with minimal effect on cortisol, prolactin, or ACTH, which distinguishes it from earlier GHRPs like GHRP-2 and GHRP-6 that produced more pronounced hormonal side effects.

Why the Ipamorelin CJC-1295 Combination Is Studied Together

The scientific interest in combining ipamorelin and CJC-1295 is based on their complementary receptor activity. CJC-1295 acts on the GHRH receptor, stimulating one pathway to GH release from pituitary somatotrophs. Ipamorelin acts on the ghrelin receptor, stimulating a separate pathway to the same endpoint. Research in pituitary cell models suggests that when both receptors are activated simultaneously, the GH output is greater than the sum of each compound’s individual effect.

The proposed synergy operates through timing as well as receptor complementarity. Ipamorelin tends to produce a relatively fast onset GH response that diminishes over a shorter timeframe. CJC-1295, particularly the DAC form, provides a more sustained receptor engagement that can maintain or amplify the GH pulse after ipamorelin’s effect has peaked. The result, in preclinical and limited human data, is a GH pulse that is larger in amplitude and longer in duration than either compound produces alone.

What the Research Actually Shows

The honest characterization of the evidence base for ipamorelin and CJC-1295 is that it sits primarily at the preclinical and early Phase 2 human level. There are no large-scale Phase 3 randomized controlled trials for either compound in isolation, and no controlled trials specifically studying the combination in humans. What exists is a meaningful preclinical dataset, one important early human study for CJC-1295, and limited human data for ipamorelin.

CJC-1295 Human Data

The most-cited human study on CJC-1295 was published in the Journal of Clinical Endocrinology and Metabolism in 2006 (Teichman et al., PMID 16352683). It enrolled healthy adult volunteers in a Phase 2 dose-escalation study examining GH and IGF-1 response. The key findings: a single injection of CJC-1295 produced approximately a 7.5-fold increase in GH pulse amplitude compared to placebo. Mean IGF-1 levels increased by 28 to 67% depending on dose, and this elevation was sustained for 6 to 8 days, consistent with the DAC-mediated half-life. No serious adverse events were observed. The study also documented that multiple doses produced dose-dependent IGF-1 increases with a cumulative response profile.

This is the foundational human evidence for CJC-1295 and it is the only published controlled human study of meaningful scale. The fact that it is a single Phase 2 study from 2006, without replication in larger or longer trials, is a real limitation that should be part of any informed conversation about this compound.

Ipamorelin Human and Preclinical Data

Human data for ipamorelin is more limited than for CJC-1295. A small pilot study examining ipamorelin’s GH-stimulating effects confirmed a significant GH pulse with minimal co-stimulation of cortisol or ACTH, validating the selectivity profile observed in animal studies. A 2020 pilot study referenced in the sports medicine literature found that elevated GH from GH secretagogue administration could help preserve quadriceps strength in patients recovering from ACL reconstructive surgery, though the study was small and used mixed compounds. Animal studies consistently demonstrate GH stimulation and downstream IGF-1 elevation with the expected metabolic effects on body composition in rodent models.

The Combination: What Preclinical Research Suggests

Direct human evidence for the CJC-1295 and ipamorelin combination specifically is not available in the peer-reviewed literature as of mid-2026. The rationale for combining them comes from receptor pharmacology, from the documented complementary mechanisms, and from preclinical research showing synergistic GH output. In research involving combined exposure, results suggest that ipamorelin’s receptor-mediated activity is observed earlier in the response profile, potentially priming GH release. As its effects diminish, CJC-1295’s prolonged receptor engagement may sustain or increase GH-related activity through continued stimulation of the GHRH pathway. This mechanistic reasoning is coherent. It does not substitute for controlled human trial data, but it provides a scientifically grounded rationale for why the combination is studied rather than either compound alone.

How Ipamorelin and CJC-1295 Compare to Sermorelin

The compound with the clearest legal status in the GH-stimulating category is Sermorelin, a 29-amino acid GHRH analog that is legally available through licensed compounding pharmacies under a valid physician prescription. Understanding how these compounds compare helps explain the clinical interest in ipamorelin and CJC-1295 and why providers who use Sermorelin find it a defensible starting point while the regulatory picture for the CJC-1295 and ipamorelin combination remains unresolved.

The Regulatory Timeline: What Has Actually Happened

The regulatory history of CJC-1295 and ipamorelin over the past three years is worth understanding clearly, because the story is more nuanced than either “they’re banned” or “they’re back.”

In September 2023, the FDA placed both compounds on Category 2 of the interim 503A Bulks List, meaning licensed compounding pharmacies could no longer legally prepare them for human use. This was a significant disruption to clinical practice.

In September 2024, following a legal challenge and a settlement with the FDA, the FDA announced that five peptide bulk drug substances, including CJC-1295 and ipamorelin acetate, were being removed from Category 2 and referred to the Pharmacy Compounding Advisory Committee for formal review. The removal became effective September 27, 2024.

However, this did not automatically clear these peptides for compounding. The PCAC subsequently voted against recommending them for inclusion in the 503A Bulks Regulation. This means compounding remains suspended while evaluation continues.

In spring 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 peptides, including CJC-1295 and ipamorelin, were expected to return to Category 1, with formal FDA reclassification announced effective April 23, 2026, and PCAC scheduled to formally review them at its July 23 and 24, 2026, meeting.

The practical implication: as of June 2026, CJC-1295 and ipamorelin cannot be legally compounded by licensed US 503A pharmacies under current rules. The PCAC review in July 2026 may change that. Anyone offering these compounds through a “licensed compounding pharmacy” before that review is finalized is not operating within the current regulatory framework.

Safety Considerations

The safety data for ipamorelin and CJC-1295 comes primarily from the 2006 Phase 2 CJC-1295 study, the small ipamorelin human pilot, and extrapolation from the broader GHRH and GHRP research literature. No serious adverse events were reported in the CJC-1295 Phase 2 study. Ipamorelin’s selectivity profile, with minimal cortisol and prolactin co-stimulation, is considered a safety advantage over earlier generation GHRPs. Common side effects reported in available data include injection site reactions, transient headache, flushing, and mild water retention, consistent with GH axis stimulation generally.

The same considerations that apply to all GH-stimulating compounds also apply here. A cancer history, particularly any hormonally sensitive malignancy, requires careful evaluation before any IGF-1-elevating protocol. Glucose metabolism should be monitored because GH can affect insulin sensitivity. And the compound source matters significantly: GH secretagogues purchased from unregulated research peptide suppliers have no quality, purity, or concentration assurance, and represent a different and less predictable risk profile than pharmaceutical-grade compounded preparations from licensed facilities. For the full pre-therapy evaluation picture, the companion article on What Labs Do You Need Before Starting Peptide Therapy covers the relevant baseline testing. For more on how GH peptides fit into the broader peptide therapy landscape, the Complete Beginner’s Guide to Peptide Therapy provides useful context.